MY170069A - Low anticoagulant heparins - Google Patents

Low anticoagulant heparins

Info

Publication number
MY170069A
MY170069A MYPI2014001796A MYPI2014001796A MY170069A MY 170069 A MY170069 A MY 170069A MY PI2014001796 A MYPI2014001796 A MY PI2014001796A MY PI2014001796 A MYPI2014001796 A MY PI2014001796A MY 170069 A MY170069 A MY 170069A
Authority
MY
Malaysia
Prior art keywords
low anticoagulant
anticoagulant heparins
antifactor
activity
less
Prior art date
Application number
MYPI2014001796A
Other languages
English (en)
Inventor
Hans-Peter Ekre
Ulf Lindahl
Erik Holmer
Per-Olov Eriksson
Anna Leitgeb
Mats Wahlgren
Stefania Tidia
Lino Liverani
Original Assignee
Modus Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modus Therapeutics Ab filed Critical Modus Therapeutics Ab
Publication of MY170069A publication Critical patent/MY170069A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2014001796A 2011-12-19 2012-12-19 Low anticoagulant heparins MY170069A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins

Publications (1)

Publication Number Publication Date
MY170069A true MY170069A (en) 2019-07-03

Family

ID=48668926

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001796A MY170069A (en) 2011-12-19 2012-12-19 Low anticoagulant heparins

Country Status (26)

Country Link
US (2) US9480702B2 (cg-RX-API-DMAC7.html)
EP (2) EP2794666B1 (cg-RX-API-DMAC7.html)
JP (2) JP6703806B2 (cg-RX-API-DMAC7.html)
CN (1) CN104053675B (cg-RX-API-DMAC7.html)
AU (1) AU2012354226B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014014673B1 (cg-RX-API-DMAC7.html)
CA (2) CA2856918C (cg-RX-API-DMAC7.html)
CY (2) CY1120197T1 (cg-RX-API-DMAC7.html)
DK (2) DK2794667T3 (cg-RX-API-DMAC7.html)
ES (2) ES2668273T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20180726T1 (cg-RX-API-DMAC7.html)
HU (2) HUE037555T2 (cg-RX-API-DMAC7.html)
IL (1) IL232903A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN01056A (cg-RX-API-DMAC7.html)
MX (1) MX358439B (cg-RX-API-DMAC7.html)
MY (1) MY170069A (cg-RX-API-DMAC7.html)
NO (2) NO2794666T3 (cg-RX-API-DMAC7.html)
PH (1) PH12014501387B1 (cg-RX-API-DMAC7.html)
PL (2) PL2794666T3 (cg-RX-API-DMAC7.html)
PT (2) PT2794666T (cg-RX-API-DMAC7.html)
RS (2) RS57214B1 (cg-RX-API-DMAC7.html)
SI (2) SI2794667T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800217T1 (cg-RX-API-DMAC7.html)
TN (2) TN2014000236A1 (cg-RX-API-DMAC7.html)
WO (3) WO2013095215A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403654B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095279A1 (en) 2011-12-19 2013-06-27 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP3137099B1 (en) * 2014-04-30 2019-09-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Dnase for use in treating vaso-occlusive crisis
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US12220500B2 (en) * 2018-04-13 2025-02-11 University Of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
WO2023192344A1 (en) * 2022-03-29 2023-10-05 The Penn State Research Foundation Device and method for accelerating and guiding vascularization
US12444880B2 (en) 2022-05-05 2025-10-14 Tego Innovations, Inc. Magnetic power distribution assembly
US20250353936A1 (en) * 2022-06-06 2025-11-20 Ihp Therapeutics Inc. Chemically modified heparin
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) * 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use
WO2024170746A1 (en) 2023-02-17 2024-08-22 Modus Therapeutics Ab New medical use of sevuparin in the treatment of endotoxemia
CN116854838A (zh) * 2023-06-30 2023-10-10 重庆望业药物研究有限公司 低分子多糖及其制备方法与应用
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
DE68906345T2 (de) * 1988-10-07 1993-10-28 Hoechst Ag Antimalariazusammenstellungen, gebrauchmachend von Quinidin, Artemisinin und ihren Derivaten.
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) * 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
ATE224918T1 (de) * 1995-03-31 2002-10-15 Hamilton Civic Hospitals Res Zusammensetzung zur hemmung der thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
EP1033375A4 (en) * 1997-11-20 2002-04-24 Ikuo Yamashina MODIFICATION OF LOW MOLECULAR MASS HEPARIN AND REMEDY FOR SKIN Ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
EP1059304B1 (en) 1998-02-26 2006-04-26 Seikagaku Corporation Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1022289B1 (en) * 1998-07-31 2004-07-07 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DK1319183T3 (da) * 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2003088980A1 (en) * 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
EP2258349B1 (en) * 2004-05-11 2014-07-16 Egalet Ltd. Swellable dosage form comprising gellan gum
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
EP1906975A4 (en) * 2005-07-22 2010-10-06 Trf Pharma Inc METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
EP1906974A4 (en) * 2005-07-22 2010-06-23 Univ California HEPARINE COMPOSITIONS AND SELECTIN INHIBITION
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
WO2009059284A2 (en) * 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
JP5758797B2 (ja) * 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
CA2767560A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd Atovaquone with a particle size diameter range (d90) of greater than 3um to about 10um
CA2758520A1 (en) 2009-04-16 2010-10-21 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
WO2011000032A1 (en) * 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013095279A1 (en) 2011-12-19 2013-06-27 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
CA2868479A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
CA2868444A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor

Also Published As

Publication number Publication date
DK2794666T3 (en) 2018-04-23
JP6703806B2 (ja) 2020-06-03
SI2794667T1 (en) 2018-06-29
JP2018154848A (ja) 2018-10-04
TN2014000237A1 (en) 2015-09-30
CA2856918A1 (en) 2013-06-27
CY1120197T1 (el) 2018-12-12
CA2856918C (en) 2017-07-04
PH12014501387A1 (en) 2014-09-22
BR112014014673A8 (pt) 2017-07-04
CY1120194T1 (el) 2018-12-12
NZ625096A (en) 2016-07-29
CA2856477A1 (en) 2013-06-27
HUE037555T2 (hu) 2018-09-28
PT2794666T (pt) 2018-05-09
NO2794667T3 (cg-RX-API-DMAC7.html) 2018-07-21
BR112014014673A2 (pt) 2017-06-13
JP2015500387A (ja) 2015-01-05
IL232903A (en) 2017-02-28
MX2014006956A (es) 2014-10-17
DK2794667T3 (en) 2018-04-23
HK1200471A1 (en) 2015-08-07
EP2794667B1 (en) 2018-02-21
US9480701B2 (en) 2016-11-01
HUE037554T2 (hu) 2018-09-28
EP2794667A1 (en) 2014-10-29
SI2794666T1 (en) 2018-06-29
WO2013095215A1 (en) 2013-06-27
HK1199893A1 (en) 2015-07-24
CN104053675B (zh) 2016-10-12
MX358439B (es) 2018-08-21
AU2012354226B2 (en) 2017-01-12
US20150031638A1 (en) 2015-01-29
HRP20180726T1 (hr) 2018-06-15
RS57214B1 (sr) 2018-07-31
EP2794666B1 (en) 2018-02-21
IL232903A0 (en) 2014-07-31
RS57213B1 (sr) 2018-07-31
NO2794666T3 (cg-RX-API-DMAC7.html) 2018-07-21
PL2794667T3 (pl) 2018-09-28
ZA201403654B (en) 2017-08-30
ES2668273T3 (es) 2018-05-17
TN2014000236A1 (en) 2015-09-30
US9480702B2 (en) 2016-11-01
CA2856477C (en) 2017-06-27
WO2013095276A1 (en) 2013-06-27
ES2669055T3 (es) 2018-05-23
SMT201800218T1 (it) 2018-05-02
AU2012354226A1 (en) 2014-06-05
BR112014014673B1 (pt) 2021-02-17
HRP20180725T1 (hr) 2018-06-29
PT2794667T (pt) 2018-05-16
EP2794667A4 (en) 2015-07-22
PL2794666T3 (pl) 2018-08-31
EP2794666A1 (en) 2014-10-29
IN2014MN01056A (cg-RX-API-DMAC7.html) 2015-05-01
US20140364369A1 (en) 2014-12-11
EP2794666A4 (en) 2015-07-22
WO2013095277A1 (en) 2013-06-27
PH12014501387B1 (en) 2014-09-22
SMT201800217T1 (it) 2018-05-02
CN104053675A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
PH12014501387A1 (en) Low anticoagulant heparins
DK2794665T3 (da) Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
EP4600271A3 (en) Bioactive molecule conjugate, preparation method and use thereof
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
MX363923B (es) Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
MX2015007410A (es) Membrana de hidrogel para prevencion de la adhesion.
NZ624749A (en) A sulfated polysaccharide compound and the preparation and use thereof
NZ631279A (en) Method for treatment of labor arrest
UA113005C2 (uk) Біотехнологічний хондроїтин-6-сульфат з низькою молекулярною масою для запобігання остеоартриту
NZ703260A (en) Polysaccharide compositions and methods of use
MX365289B (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alfa-2c.
CY1121728T1 (el) Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα
EP4620535A3 (en) Improvements in or relating to organic compounds
FR2978665B1 (fr) Composition antiseptique
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
GB201012333D0 (en) Fibres, a process for producing such fibres and a wound dressing incorporating them
WO2011155800A3 (ko) 히알루론산의 탈아세틸화 가수분해효소, 및 이에 의해 탈아세틸화된 히알루론산 및 이의 유도체
JP2007126453A5 (cg-RX-API-DMAC7.html)
MX2012006966A (es) Tratamiento de padecimientos mediados por citocina.
TH154800A (th) เฮพารินที่ต้านการแข็งตัวของเลือดได้ต่ำ (Low Anticoagulant Heparins)
WO2012099999A3 (en) Methods and compositions for inducing weight loss
EP3594686A3 (en) Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
MX371198B (es) Terapia antidiabetica vasoprotectora y cardioprotectora.
Wang et al. Total Synthesis of Anticoagulant Pentasaccharide Fondaparinux
Franzè et al. Influence of chemical and structural features on skin penetration of low molecular weight heparins